
Novartis’ Cosentyx shows no benefit in Phase III GCA trial
Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), Cosentyx was evaluated in combination with a 26-week steroid …